Uniqure NVQURE
▼ NegativeCapitalrelevance
UniQure launches a $150M public offering, diluting existing shareholders.
Impact on stocks 1
Biotech & Genomic Medicine
Uniqure NVUniQure has launched a proposed $150 million underwritten public offering to strengthen its balance sheet and support ongoing development programs. The offering includes ordinary shares and, for certain investors, pre-funded warrants exercisable for ordinary shares, with all securities sold by the company. Underwriters will have a 30-day option to purchase up to an additional $22.5 million in ordinary shares on the same terms. The offering remains subject to market conditions, and there is no assurance regarding its timing, size, or completion. Leerink Partners and Stifel are serving as joint bookrunning managers.
Uniqure NVUniQure launches a $150M public offering, diluting existing shareholders.